ImageneBio Taps Yanina Grant-Huerta as CFO While CMO Shifts to Consulting
IMA sits 41% above its 52-week low of $3.94 on light trading volume (0.2× avg).
Summary
ImageneBio appointed Yanina Grant-Huerta as CFO and announced the transition of its Chief Medical Officer to a consulting role, marking two senior leadership changes in quick succession.
Key Events · Executive and Board Changes · IMA
-
New CFO Appointed
Effective July 20, 2026, Yanina Grant-Huerta steps in as CFO with a compensation package that includes a $450,000 base salary, a 40% target bonus, 65,000 RSUs, and 95,000 stock options.
-
CMO Transition to Consulting
Chief Medical Officer Benjamin Porter-Brown will transition to a consulting role effective July 24, 2026, reducing his full-time involvement.
-
Leadership Vacuum Filled
The appointment fills the principal financial officer role left vacant by the resignation of SVP Robert Lally on June 26, 2026.
-
Resale Shelf Updated
The prospectus supplement updates the resale registration for 2,508,337 shares, originally filed in May 2026, with the attached 8-K disclosures.
Analysis · IMA · Life Sciences
Filling the vacancy left by the prior finance head's resignation in June, ImageneBio has appointed Yanina Grant-Huerta as CFO. She brings experience from Atara Biotherapeutics and Amgen, and her compensation package includes a $450,000 salary, a 40% bonus target, and equity grants of 65,000 RSUs and 95,000 options. At the same time, Chief Medical Officer Benjamin Porter-Brown will move to a consulting role, scaling back his day-to-day involvement. These back-to-back leadership changes follow a period of significant dilution and a recent $30 million private placement, raising questions about stability and strategic direction.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.3% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMA was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.8M. The 52-week trading range was $3.94 to $213.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.